AKBA Stock News & Catalysts – Akebia Therapeutics

FEATURED

Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of

Summary

Nov 5, 2026, 7:10 AM ·Globe Newswire

RECENT

Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin

WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced

Nov 5, 2026, 7:00 AM ·Globe Newswire

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on Thursday, November

Oct 29, 2026, 8:00 AM ·Globe Newswire

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S.

Oct 26, 2026, 9:20 AM ·Globe Newswire

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that

Oct 7, 2026, 8:00 AM ·Globe Newswire

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced

Oct 6, 2026, 8:00 AM ·Globe Newswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one

Oct 1, 2026, 4:05 PM ·Globe Newswire

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia

Sep 14, 2026, 8:00 AM ·Globe Newswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one

Sep 1, 2026, 4:05 PM ·Globe Newswire

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Sep 1, 2026, 8:00 AM ·Globe Newswire

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket

Aug 5, 2026, 4:05 PM ·Globe Newswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2

Aug 3, 2026, 4:05 PM ·Globe Newswire

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Aug 3, 2026, 8:00 AM ·Globe Newswire

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wednesday, August 5,

Jul 29, 2026, 8:00 AM ·Globe Newswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3

Jul 2, 2026, 4:05 PM ·Globe Newswire

Akebia Therapeutics, Inc. AKBA · News